Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316474 | 0.80 | ALOX5 (0.44) | — | |
| SCHEMBL1044396 | 0.80 | TACR3 (0.34) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL31510779 | 0.78 | KDM1A (0.36) | ALDH1A1KDM4EMEN1USP2LMNA | |
| SCHEMBL12747180 | 0.78 | EPHX2 (0.43) | KDM4ETDP1 | |
| SCHEMBL23651895 | 0.78 | NCF1 (0.46) | LMNA | |
| SCHEMBL3317695 | 0.75 | EPHX2 (0.49) | ALDH1A1NPC1 | |
| SCHEMBL3311715 | 0.74 | MAPT (0.51) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3317367 | 0.74 | MEN1 (0.43) | ALDH1A1MEN1USP2KMT2A | |
| SCHEMBL3316244 | 0.74 | CXCR3 (0.38) | ALDH1A1MEN1CYP3A4KMT2ANPC1 | |
| SCHEMBL25335914 | 0.72 | TACR3 (0.39) | ALDH1A1KDM4EMEN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | DONG-A-PHARM. CO., LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | HTR4, HTR1A, TPH1 | ALDH1A1 1208/4885KDM4E 2301/4885MEN1 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.